AstraZeneca: Lynparza Approved in EU to Treat a Form of Breast Cancer
April 10 2019 - 2:57AM
Dow Jones News
By Ian Walker
AstraZeneca PLC (AZN.LN) and Merck & Co. Inc. (MRK) said
Wednesday that the European Commission has approved Lynparza as a
monotherapy for the treatment of germline BRCA-mutated metastatic
breast cancer.
AstraZeneca's executive vice president of oncology, Dave
Fredrickson, said the approval enables Lynparza to provide patients
throughout the EU with a targeted and oral chemotherapy-free
treatment option for a difficult-to-treat cancer.
Advanced/metastatic breast cancer refers to Stage III and IV
breast cancer, while BRCA are human genes that produce proteins
responsible for repairing damaged DNA.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 10, 2019 02:42 ET (06:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
